Savara Highlights New P-III (IMPALA-2) Study Data of Molgramostim to Treat Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at ERS 2024
Shots:
- The P-III (IMPALA-2) study assesses the safety & efficacy of molgramostim (300mcg, self-administered by inhalation, QD) vs PBO for the treatment of aPAP for 48wks.
- The trial previously reached its 1EP, showing significant improvement in hemoglobin-adjusted DLCO% at wk.24, maintained till wk.48. Molgramostim also improved the SGRQ Total Score (2EP) along with SGRQ Activity Score at wk.24 and exercise capacity at wk.48
- New results demonstrated improved disease severity scores and DLCO% responder rates at wks.24 & 48. SGRQ Total Score responder analysis showed higher response rates with molgramostim, that improved at wk.48. GGO score, evaluating surfactant burden, also improved at wk.24. Savara plans to submit the BLA by H1’25
Ref: Savara | Image: Savara
Related News:- GSK Reports the P-III Study Results of Nucala (Mepolizumab) for Treating Chronic Obstructive Pulmonary Disease (COPD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
